Clinerion will present its Patient Recruitment System, which allows real-time patient search for clinical trials via direct query of electronic health records, for the first time in North America at the SCOPE Summit and the HX360 Executive Forum, part of the HIMMS Health IT Conference.
Basel, January 25, 2016 – Clinerion will introduce its clinical research solutions in North America at SCOPE, the Summit for Clinical Ops Executives, and HX360, the Executive Forum for health and technology innovation (part of the HIMMS Health IT Conference). At both events, Clinerion will give live demonstrations of its Patient Recruitment System (PRS) and Quality Risk Management (QRM) system.
Visitors will be able to see how PRS enables electronic health record-driven protocol feasibility and real-time patient recruitment. PRS allows trial teams to optimize protocols and to assess the possible number of suitable patients 24 hours a day, 7 days a week, identifying 10 to 30 times more patients compared to classical, manual screening, and giving results within minutes rather than the weeks, or months typically needed. Research hospitals can also recruit patients much quicker and with higher precision than with traditional screening. Within PRS, patient privacy is maintained and compliant with international standards such as HIPAA, and the FDA, as patient data is never removed from the hospital premises and are de-identified before query.
These events also represent the very first opportunity to experience the brand new risk analytics interface of Clinerion's cloud-based QRM System.
Clinerion is a Corporate Sponsor of the SCOPE Summit and will be exhibiting at Stand 505, in the exhibition hall. The SCOPE Summit takes place in Miami, USA, on February 23-25, 2016. SCOPE comprises conferences, workshops and symposia on topics related to clinical trial planning and management.
In addition, at the SCOPE Summit conference “Leveraging Existing Data for Clinical and Observational Research,” Randy Ramin-Wright, Clinerion’s Director, Business Development, USA, will chair the Real-World Data track “Cross-Linking Data Sources” discussion about issues surrounding secondary use of existing healthcare data.
Clinerion will also be at the HX360 Executive Forum in Las Vegas, USA, February 29-March 3, 2016. Come join us at booth #60 in the Innovation Pavilion of HX360. The Innovation Pavilion is the platform for innovators to engage with emerging technology companies bringing transformative technologies to the healthcare industry. Running on a parallel track with and in the same location as HIMSS16, the Health IT conference and exhibition, HX360 is a healthcare innovation forum for executive leadership.
About Clinerion
Clinerion is a Swiss-based technology services company with international operations offering highly scalable electronic patient recruitment and quality risk management solutions to increase efficiency and quality in clinical research. The company's Patient Recruitment System connects to, aggregates and leverages existing electronic medical records. Following international privacy and confidentiality standards, Clinerion's solutions pseudonimyze, enrich and normalize those records and facilitate real-time patient recruitment for clinical trials. Clinerion's Quality Risk Management system leverages clinical research data, analyzes these data with leading risk management methodologies (FMEA) and facilitates risk control using risk intervention tools all based on ICH Q9 and E6(R2) Guidance for Industry on Quality Risk Management and Risk Based Monitoring (RBM).
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.